MediPharm’s Bleak Outlook; Cannabis Watchlist Updates – Money and Markets

In this week’s Marijuana Market Update, I provide some analysis on MediPharm Lab Corp.’s stock and have an update for the Cannabis Watchlist.

If you’ve been investing for any amount of time, you’ve run across a common saying as any stock takes a dive.

“Buy the dip,” investors of all kinds suggest.

It can be tempting, especially in an exciting and ever-changing market like cannabis, to take chances, to be risky and buy a dip in a stock. I’m not advising against that approach — I just want to make sure your approach is strategic.

Predicting the bottom for a stock is almost impossible. That’s why our strategy at Money & Markets is to target stocks in an uptrend.

In today’s Marijuana Market Update, I showcase a cannabis stock that highlights the risks of buying the dip.

I learned about this company from Melanie, who emailed me at

She said:

Love your platform. Straight-forward information with no BS. Excellent job, and keep up the great work.

Would you mind looking into MediPharm Labs for us? It used to be a hot stock but it seems it has fallen off the radar totally.

Thank you!


Thank you for your email and kind comments, Melanie!

About MediPharm Labs Corp.

MediPharm Labs Corp. (OTC: MEDIF) is a Canada-based company that produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia.

It also provides contract-processing services to licensed cannabis producers and growers in Canada.

Melanie is right: The company fell off the radar after reaching highs in late 2019.

This is due, in part, to a drastic drop in revenue. The company‘s total revenue dropped 72% from 2019 to 2020.

MediPharm’s revenue went from $13.9 million in the second quarter

Read More Here...

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top